242 related articles for article (PubMed ID: 23979162)
1. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.
Vincent LM; Tran S; Livaja R; Bensend TA; Milewicz DM; Dahlbäck B
J Clin Invest; 2013 Sep; 123(9):3777-87. PubMed ID: 23979162
[TBL] [Abstract][Full Text] [Related]
2. Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.
Broze GJ; Girard TJ
J Clin Invest; 2013 Sep; 123(9):3710-2. PubMed ID: 23979154
[TBL] [Abstract][Full Text] [Related]
3. Factor V east Texas variant causes bleeding in a three-generation family.
Peterson JA; Gupta S; Martinez ND; Hardesty B; Maroney SA; Mast AE
J Thromb Haemost; 2022 Mar; 20(3):565-573. PubMed ID: 34847292
[TBL] [Abstract][Full Text] [Related]
4. Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
van Doorn P; Rosing J; Duckers C; Hackeng TM; Simioni P; Castoldi E
Thromb Haemost; 2018 Jul; 118(7):1194-1202. PubMed ID: 29864781
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.
Dahlbäck B
J Thromb Haemost; 2017 Jul; 15(7):1241-1250. PubMed ID: 28671348
[TBL] [Abstract][Full Text] [Related]
6. Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
van Doorn P; Rosing J; Campello E; Middeldorp S; Simioni P; Meijers JCM; Hackeng TM; Castoldi E
Thromb Haemost; 2020 Jan; 120(1):55-64. PubMed ID: 31705518
[TBL] [Abstract][Full Text] [Related]
7. F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.
Zimowski KL; Petrillo T; Ho MD; Wechsler J; Shields JE; Denning G; Jhita N; Rivera AA; Escobar MA; Kempton CL; Camire RM; Doering CB
J Thromb Haemost; 2021 Jul; 19(7):1653-1665. PubMed ID: 33773040
[TBL] [Abstract][Full Text] [Related]
8. Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
Petrillo T; Ayombil F; Van't Veer C; Camire RM
J Biol Chem; 2021; 296():100234. PubMed ID: 33376137
[TBL] [Abstract][Full Text] [Related]
9. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
Dahlbäck B
Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
[TBL] [Abstract][Full Text] [Related]
10. A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.
Dahlbäck B; Tran S
J Thromb Haemost; 2022 May; 20(5):1146-1157. PubMed ID: 35247027
[TBL] [Abstract][Full Text] [Related]
11. Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short.
Dahlbäck B
J Thromb Haemost; 2023 Apr; 21(4):716-727. PubMed ID: 36746318
[TBL] [Abstract][Full Text] [Related]
12. The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg
van Doorn P; Rosing J; Wielders SJ; Hackeng TM; Castoldi E
J Thromb Haemost; 2017 Jan; 15(1):140-149. PubMed ID: 27801970
[TBL] [Abstract][Full Text] [Related]
13. The preAR2 region (1458-1492) in factor V-Short is crucial for the synergistic TFPIα-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPIα.
Dahlbäck B; Tran S
J Thromb Haemost; 2022 Jan; 20(1):58-68. PubMed ID: 34623729
[TBL] [Abstract][Full Text] [Related]
14. Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.
Mast AE
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):9-14. PubMed ID: 26603155
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
Wood JP; Bunce MW; Maroney SA; Tracy PB; Camire RM; Mast AE
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17838-43. PubMed ID: 24127605
[TBL] [Abstract][Full Text] [Related]
16. New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short.
Dahlbäck B; Guo LJ; Zöller B; Tran S
J Thromb Haemost; 2019 Apr; 17(4):585-595. PubMed ID: 30740865
[TBL] [Abstract][Full Text] [Related]
17. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.
Dahlbäck B; Guo LJ; Livaja-Koshiar R; Tran S
Res Pract Thromb Haemost; 2018 Jan; 2(1):114-124. PubMed ID: 30046712
[TBL] [Abstract][Full Text] [Related]
18. The TFPIα C-terminal tail is essential for TFPIα-FV-short-protein S complex formation and synergistic enhancement of TFPIα.
Gierula M; Noakes VM; Salles-Crawley II; Crawley JTB; Ahnström J
J Thromb Haemost; 2023 Dec; 21(12):3568-3580. PubMed ID: 37739040
[TBL] [Abstract][Full Text] [Related]
19. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function.
Cunha ML; Bakhtiari K; Peter J; Marquart JA; Meijers JC; Middeldorp S
Blood; 2015 Mar; 125(11):1822-5. PubMed ID: 25634741
[TBL] [Abstract][Full Text] [Related]
20. Cryo-EM structure of coagulation factor V short.
Mohammed BM; Pelc LA; Rau MJ; Di Cera E
Blood; 2023 Jun; 141(26):3215-3225. PubMed ID: 36862974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
